Fibromyalgia Diet Trial: Symptoms Improved, Biomarkers Did Not

A structured diet improved pain and other self-reported fibromyalgia symptoms in a controlled trial. It did not change either blood marker of inflammation the researchers measured. That split result is the useful part: diet may help some people feel better, especially those with gut symptoms, without proving that it treats fibromyalgia through systemic anti-inflammatory effects.

The evidence is encouraging enough to justify a supervised, time-limited experiment for selected patients. It is far too small to support claims that an "anti-inflammatory" diet reverses fibromyalgia, repairs the microbiome, or replaces established care.

A small trial found symptom improvement against an active diet control

In a 2022 randomized controlled trial by Silva et al., 62 women meeting ACR 2010 fibromyalgia criteria enrolled at the Portuguese Institute of Rheumatology; 46 completed three months. The intervention combined an anti-inflammatory eating pattern with a temporary low-FODMAP phase. During month one, participants avoided rapidly fermentable carbohydrates while following a gluten-free, dairy-free, sugar-free, ultra-processed-food-free pattern enriched with omega-3 sources and antioxidant-rich foods. During months two and three, they continued the anti-inflammatory pattern while fruits and vegetables were reintroduced.

The comparison group did not receive no advice. It received a World Health Organization–compliant healthy diet. That is a better comparator than a waitlist because it tests the specific protocol against reasonable dietary counseling, though it also makes large between-group differences harder to find.

The intervention group improved relative to control on all six patient-reported measures, including the Revised Fibromyalgia Impact Questionnaire, visual analog pain ratings, and Brief Pain Inventory domains. Those are outcomes patients care about. However, the published abstract available here does not provide the mean changes, confidence intervals, or whether participants reached established thresholds for clinically important improvement. We therefore know the direction of the result, but not its exact size.

Neither high-sensitivity C-reactive protein nor erythrocyte sedimentation rate changed significantly in either group. The trial had no microbiome sequencing, so it cannot show that the diet altered gut bacteria. It also cannot separate the effect of reducing FODMAPs from the effect of removing ultra-processed foods, dairy, gluten, and added sugar.

The biomarker result changes the most credible explanation

Fibromyalgia commonly overlaps with irritable bowel syndrome. A 2025 systematic review of the fibromyalgia–IBS association reported co-occurrence above 30% and described shared features that include visceral hypersensitivity, altered gut motility, and central sensitization. For people with both conditions, reducing fermentable carbohydrates could ease bloating, bowel symptoms, and gut-related pain amplification. That is a more evidence-based explanation than assuming the diet lowered body-wide inflammation.

The indirect evidence is stronger for IBS than for fibromyalgia. A 2025 network meta-analysis of dietary randomized trials in IBS evaluated dietary approaches, including low-FODMAP diets, for IBS symptom relief. It supports the idea that a low-FODMAP phase can reduce gut symptom burden. It does not establish that treating IBS symptoms changes fibromyalgia biology or improves fibromyalgia for people without meaningful gastrointestinal symptoms.

Gut-brain signaling remains plausible but unproven. A 2026 observational study linked differences in gut microbiota composition in people with fibromyalgia to symptom severity. Cross-sectional findings cannot tell whether microbiota differences contribute to symptoms, result from illness and treatment, or track another factor entirely. Medication use is a particular problem because drugs commonly used in fibromyalgia can also affect gut microbiota.

A 2025 systematic review of microbiota-modulating interventions found emerging human evidence relevant to pain, cognition, mood, and neuroinflammation in fibromyalgia-related contexts. A broader meta-analysis of 80 randomized trials also supports the general principle that gut microbiota-based therapies can affect outcomes in autoimmune and rheumatic diseases. Fibromyalgia is not classically autoimmune, however, and neither review supplies the missing chain of evidence: diet changes microbiota, microbiota changes, and fibromyalgia symptoms improve because of those changes.

The wider diet literature is consistent, but still immature

Two systematic reviews reach a similar cautious conclusion. A 2025 review of Mediterranean and anti-inflammatory diets identified only 10 eligible studies published from 2019 through 2024: five interventions with samples of 13 to 84 participants and five observational studies with 84 to 442 participants. The studies reported low-to-moderate symptom improvement, but none had the scale to reliably detect biomarker effects.

A 2023 systematic review found similarly limited, directionally positive signals for vegetarian, gluten-free, low-FODMAP, and elimination approaches. Short duration, small samples, open-label designs, and reliance on patient reports recur across this literature. Dietary trials cannot realistically blind participants, and attention from a dietitian can itself influence expectations, adherence, and symptom reporting.

Observational evidence offers a reason to study food quality, not proof that changing it treats fibromyalgia. A 2025 case-control study found higher ultra-processed-food consumption and a more pro-inflammatory dietary load among adults diagnosed with fibromyalgia than among controls. Fibromyalgia could affect shopping, cooking, appetite, and energy; shared behavioral or socioeconomic factors could also explain part of the association.

Why "anti-inflammatory" is an overconfident label

The term sounds more settled than the evidence allows. In the Silva trial, symptoms improved while hs-CRP and ESR did not. One explanation is that the diet helped through gut symptom reduction or other behavioral changes rather than systemic inflammation. Another is that these markers miss processes relevant to fibromyalgia. The trial's 46 completers also leave limited power to detect biomarker differences. The data cannot choose among those explanations.

Evidence from rheumatoid arthritis reinforces the need for restraint. A 2022 systematic review and meta-analysis found only modest pain reduction and limited effects on objective inflammatory markers from anti-inflammatory diets in rheumatoid arthritis, a disease with clearer measurable systemic inflammation. That does not rule out dietary symptom benefits in fibromyalgia. It does make a large systemic anti-inflammatory effect less likely.

How to use this evidence without turning food into another burden

A three-month, clinician- or dietitian-supervised trial is reasonable as an adjunct for people with fibromyalgia and substantial IBS-like symptoms. Set a symptom target before starting—such as abdominal symptoms, pain interference, sleep, or fatigue—and reassess at the end. If the diet adds stress, expense, nutritional problems, or no meaningful benefit, stop rather than treating adherence as a moral achievement.

• Keep the low-FODMAP restriction temporary. In the positive trial it lasted one month, followed by food reintroduction. Prolonged restriction can reduce fermentable substrates for gut bacteria, and no fibromyalgia trial has shown that sustained restriction improves the microbiome.
• Do not stack exclusions casually. The trial removed dairy, gluten, added sugar, and ultra-processed foods alongside FODMAP restriction, so no component has earned credit on its own.
• Review nutritional adequacy. A 2025 study of 68 women with fibromyalgia reported inverse associations between vitamin D status and inflammatory pain-related measures and examined dysbiosis markers. Removing dairy can further complicate calcium and vitamin D intake, so a clinician should assess individual needs.
• Continue evidence-based fibromyalgia care. The diet trial tested an adjunct, not a replacement for medical evaluation, movement strategies, sleep management, psychological support, or prescribed treatment.

The honest conclusion is modest: this protocol produced a real patient-reported signal in a small, open-label trial, but it did not move the measured inflammatory biomarkers or demonstrate a microbiome mechanism. Its best current use is a monitored trial for people whose fibromyalgia includes prominent gastrointestinal symptoms.

No major rheumatology or pain society has issued formal dietary guidelines for fibromyalgia. Until larger, longer trials measure clinical outcomes, nutritional safety, biomarkers, and microbiome changes together, diet remains a reasonable experiment—not a proven disease-modifying treatment.